Ubs Group Ag Ambrx Biopharma Inc. Transaction History

Ubs Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$9.3 - $16.6 $51,838 - $92,528	5,574 New	5,574 $64,000
Q1 2023 May 12, 2023	BUY	$1.46 - $12.54 $78,583 - $674,952	53,824 Added 1768.2%	56,868 $507,000
Q4 2022 Feb 08, 2023	SELL	$0.41 - $4.54 $2,018 - $22,350	-4,923 Reduced 61.79%	3,044 $6,000
Q3 2022 Nov 10, 2022	BUY	$1.06 - $2.96 $8,188 - $22,866	7,725 Added 3192.15%	7,967 $9,000
Q2 2022 Aug 10, 2022	BUY	$2.53 - $4.35 $612 - $1,052	242 New	242 $1,000

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.